US Stock MarketDetailed Quotes
VERV Verve Therapeutics
- 5.290
- +0.440+9.07%
Close Nov 25 16:00 ET
- 5.190
- -0.100-1.89%
Post 17:16 ET
447.87MMarket Cap-2150P/E (TTM)
5.480High4.946Low2.56MVolume4.960Open4.850Pre Close13.64MTurnover4.57%Turnover RatioLossP/E (Static)84.66MShares19.34052wk High0.88P/B295.92MFloat Cap4.30552wk Low--Dividend TTM55.94MShs Float78.000Historical High--Div YieldTTM11.01%Amplitude4.305Historical Low5.335Avg Price1Lot Size
Verve Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -235.34%-39.61M | 28.78%-34.16M | 12.25%-43.08M | -22.25%-149.55M | -23.68%-40.68M | 59.52%-11.81M | -79.24%-47.96M | -46.52%-49.1M | -57.08%-122.33M | -17.29%-32.89M |
| Net income from continuing operations | -9.56%-50.13M | 7.74%-49.81M | 6.23%-48.74M | -27.12%-200.07M | -17.69%-48.35M | -1.26%-45.76M | -31.84%-53.98M | -72.30%-51.98M | -30.81%-157.39M | -31.11%-41.09M |
| Depreciation and amortization | 19.00%1.75M | 24.68%1.67M | 44.81%1.63M | 94.54%5.46M | 64.00%1.52M | 105.58%1.47M | 106.33%1.34M | 119.26%1.13M | 82.67%2.8M | 95.97%925K |
| Other non cash items | 97.29%1.82M | -94.90%120K | 89.04%1.69M | 173.73%6.63M | 547.91%2.46M | -79.87%923K | 636.76%2.35M | 175.89%894K | -93.13%2.42M | 14.49%-549K |
| Change In working capital | -104.28%-1.12M | 292.73%5.75M | -22.08%-4.04M | 111.25%17.7M | -168.22%-2.22M | 434.08%26.22M | -138.12%-2.98M | 56.49%-3.31M | 387.77%8.38M | 9,670.59%3.25M |
| -Change in receivables | 120.14%410K | 208.09%2.69M | -88.03%168K | -482.21%-5.89M | -3,243.37%-2.78M | ---2.04M | ---2.49M | --1.4M | ---1.01M | ---83K |
| -Change in prepaid assets | -155.12%-1.82M | -992.28%-4.27M | 71.44%-672K | 85.10%-1.41M | 1,836.76%1.18M | 88.99%-713K | 111.85%479K | -304.79%-2.35M | -25.35%-9.44M | 96.35%-68K |
| -Change in payables and accrued expense | -120.94%-311K | 313.49%7.11M | -771.55%-6.96M | 101.59%3.68M | -64.42%1.27M | 125.13%1.49M | -86.12%1.72M | 90.31%-798K | -85.75%1.83M | -58.42%3.58M |
| -Change in other current liabilities | -15.41%-1.22M | 55.60%-1.2M | 21.10%-1.23M | -139.79%-7.22M | -1,017.65%-1.9M | 40.99%-1.06M | -413.90%-2.7M | -199.04%-1.56M | 63.24%-3.01M | 97.49%-170K |
| -Change in other working capital | --1.82M | --1.43M | --4.65M | 42.61%28.54M | --2K | ---- | ---- | ---- | --20.01M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -235.34%-39.61M | 28.78%-34.16M | 12.25%-43.08M | -22.25%-149.55M | -23.68%-40.68M | 59.52%-11.81M | -79.24%-47.96M | -46.52%-49.1M | -57.08%-122.33M | -17.29%-32.89M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 580.07%56.81M | -8.71%30.15M | -370.48%-41.63M | 117.76%27.69M | 94.72%-8.89M | 78.68%-11.83M | 324.38%33.03M | -74.39%15.39M | 34.77%-155.96M | -195.36%-168.31M |
| Net PPE purchase and sale | 11.78%-936K | 63.19%-980K | 87.17%-433K | 29.84%-9.28M | 56.02%-2.19M | 59.76%-1.06M | 2.10%-2.66M | -16.06%-3.38M | -203.56%-13.23M | -406.42%-4.97M |
| Net investment purchase and sale | 636.04%57.75M | -12.77%31.13M | -319.53%-41.2M | 125.91%36.97M | 95.89%-6.71M | 79.63%-10.77M | 239.84%35.69M | -70.21%18.77M | 39.20%-142.72M | -191.67%-163.35M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 580.07%56.81M | -8.71%30.15M | -370.48%-41.63M | 117.76%27.69M | 94.72%-8.89M | 78.68%-11.83M | 324.38%33.03M | -74.39%15.39M | 34.77%-155.96M | -195.36%-168.31M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -99.96%14K | 5.27%1.3M | 1,015.51%22.73M | -35.38%212.58M | 347.96%177.38M | -88.93%31.92M | 177.08%1.23M | 303.56%2.04M | -12.76%328.96M | 3,135.13%39.6M |
| Net common stock issuance | --0 | 21.54%-51K | 1,031.56%22.48M | -35.54%210.46M | 358.21%176.82M | -88.99%31.71M | ---65K | --1.99M | 14.47%326.5M | --38.59M |
| Net preferred stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Proceeds from stock option exercised by employees | -93.43%14K | 5.27%1.3M | 159.48%301K | -20.50%2.58M | -14.25%1.02M | -80.78%213K | 177.08%1.23M | -77.03%116K | 85.80%3.24M | -2.95%1.19M |
| Net other financing activities | ---- | ---- | 21.54%-51K | 41.51%-458K | ---- | ---- | ---- | ---65K | 78.43%-783K | -9,000.00%-178K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -99.96%14K | 5.27%1.3M | 1,015.51%22.73M | -35.38%212.58M | 347.96%177.38M | -88.93%31.92M | 177.08%1.23M | 303.56%2.04M | -12.76%328.96M | 3,135.13%39.6M |
| Net cash flow | ||||||||||
| Beginning cash position | 95.37%146.26M | 68.20%148.97M | 75.45%210.95M | 72.83%120.24M | -70.50%83.14M | -4.17%74.87M | -8.37%88.57M | 72.83%120.24M | 635.69%69.57M | 83.77%281.84M |
| Current changes in cash | 108.01%17.22M | 80.22%-2.71M | -95.73%-61.98M | 79.04%90.72M | 179.09%127.81M | -95.94%8.28M | 26.05%-13.7M | -216.89%-31.67M | -15.71%50.67M | -92.84%-161.61M |
| End cash Position | 96.63%163.48M | 95.37%146.26M | 68.20%148.97M | 75.45%210.95M | 75.45%210.95M | -70.50%83.14M | -4.17%74.87M | -8.37%88.57M | 72.83%120.24M | 72.83%120.24M |
| Free cash flow | -214.97%-40.54M | 30.59%-35.14M | 17.07%-43.52M | -17.16%-158.83M | -13.22%-42.87M | 59.54%-12.87M | -71.74%-50.62M | -44.09%-52.47M | -64.84%-135.56M | -30.44%-37.86M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data